On Wednesday, GSK Plc (NYSE:GSK) announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all its asthma and chronic obstructive pulmonary disease (COPD) ...
LONDON, March 16 (Reuters) - Adding GlaxoSmithKline Plc's top-selling drug Advair to Pfizer Inc's Spiriva does not reduce exacerbations in patients with COPD, or smoker's lung, according to new ...
According to Nuvama, the increased competitive intensity following this approval is negative for Cipla, as it raises the risk to market share and peak sales expectations for its Advair inhaler ...
(Reuters) -British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible patients in ...
LONDON (Reuters) - GlaxoSmithKline's top-selling respiratory drug Advair is set to lose business to Spiriva, marketed by Pfizer and Boehringer Ingelheim, according to analysts at Morgan Stanley. Sign ...
A generic fluticasone-salmeterol (Wixela Inhub) maintenance inhaler was clinically equivalent to name-brand Advair Diskus for chronic obstructive pulmonary disease (COPD), a propensity score-matched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results